Kisspeptin | PeptideLibraryHub

Studied Benefits

Increased LH and FSH release (upstream of testosterone/estrogen)
Improved sexual/emotional brain responses in HSDD research
Restoration of reproductive hormone signaling in hypothalamic amenorrhea
Supportive role in assisted reproduction (IVF trigger studies)
Studied in male hypogonadism

Protocol At-a-Glance

Common Research Dose: Varies widely: IV bolus 0.3 nmol/kg to continuous infusion in trials; SubQ research use often 50–200 mcg
Studied Range: Dose-finding still active; highly protocol-specific
Frequency: Pulsatile or as-needed in human trials
Timing: Context-dependent (pre-stimulation, pre-event)
Fasting: Not required
Reconstitution: 2 mL BAC water per 5 mg vial (standard)
Storage: Refrigerate 2–8°C after reconstitution
Typical Cycle: Not well-defined outside research settings
Route: Subcutaneous or intravenous (research)

⚠️ Start Low, Go Slow: Kisspeptin doses in human trials span a wide range because researchers are still mapping dose-response. It directly drives LH/FSH and therefore sex hormone production, pushing doses high can meaningfully shift endocrine function. This is not a cosmetic peptide; it acts on core reproductive hormone signaling. Clinical supervision is strongly advised.

Overview

Kisspeptin is a neuropeptide encoded by the KISS1 gene. It acts on the KISS1R (formerly GPR54) receptor on GnRH (gonadotropin-releasing hormone) neurons in the hypothalamus. In simple terms: kisspeptin is the on-switch for the reproductive axis. When kisspeptin signaling fails, puberty doesn't start; when it works, the downstream cascade of GnRH → LH/FSH → testosterone/estrogen follows.

Its discovery as the master regulator of puberty (early 2000s) reshaped reproductive endocrinology. Most modern research interest comes from the group at Imperial College London (Prof. Waljit Dhillo and colleagues), who have run human trials showing kisspeptin can increase reproductive hormones, enhance sexual and emotional brain responses in HSDD, and restore function in hypothalamic amenorrhea.

Commonly researched forms include Kisspeptin-10 (KP-10, the biologically active shortest fragment) and Kisspeptin-54 (KP-54, the full-length endogenous form with a longer half-life).

Plain-English Summary

A naturally occurring peptide that is the master upstream regulator of reproductive hormones (GnRH, then LH, FSH, testosterone, estrogen). In clinical trials for HSDD, hypothalamic amenorrhea, and IVF use. Not FDA-approved for any consumer indication yet.

Why people are looking into this peptide

What people typically want from it

People researching Kisspeptin are usually dealing with low libido, hormonal issues (like low testosterone or irregular cycles), or fertility challenges. They typically want to:

Boost natural testosterone or estrogen production
Improve libido and sexual desire (in both men and women)
Support fertility and reproductive hormone balance
Restore normal cycles after hypothalamic amenorrhea
Work with the body's own hormonal signaling rather than replacement

FDA / Regulatory Status

In Clinical Trials As of April 2026.

Kisspeptin is not FDA-approved. Multiple academic clinical trials have been published, and active investigator-led research continues, but no commercial drug development has reached late-stage regulatory submission. It is available only in research contexts and compounded preparations.

Mechanism of Action

KISS1R agonism: Binds KISS1R on hypothalamic GnRH neurons.
GnRH release: Triggers pulsatile GnRH secretion into the hypophyseal portal system.
Pituitary LH/FSH surge: Drives gonadotropin release.
Downstream sex steroids: LH/FSH stimulate the testes (testosterone) or ovaries (estradiol, progesterone).
CNS effects: Functional MRI studies show kisspeptin modulates limbic and paralimbic brain regions involved in sexual arousal and emotional processing, effects that appear independent of its peripheral hormonal actions.

Published Research Applications

HSDD in women: Comby-Jaillet-like fMRI and self-report trials at Imperial College showed enhanced sexual-stimulus brain response vs placebo in women with HSDD.
HSDD in men: Parallel trials in men with distressing low sexual desire showed increased brain activity in sexual-processing regions with kisspeptin infusion.
Hypothalamic amenorrhea: Kisspeptin restores LH pulsatility in women with stress/exercise-related loss of cycles.
IVF trigger: Kisspeptin-54 has been studied as an alternative to hCG for triggering oocyte maturation, with a favorable OHSS risk profile.
Male hypogonadism: Studied as a way to drive endogenous testosterone production while preserving fertility.
Pubertal disorders: Research interest in kisspeptin antagonists for precocious puberty and agonists for hypogonadotropic hypogonadism.

Potential Side Effects

Published human trials report a favorable safety profile at doses studied. Reported effects include:

Side Effect	Frequency	Severity	Notes
Injection site reaction	Common	Mild	Localized redness
Transient flushing	Occasional	Mild	Short-lived vasomotor response
Headache	Occasional	Mild	Usually transient
Nausea	Uncommon	Mild	Dose-dependent
Endocrine shift	Expected effect	Moderate	LH/FSH and sex steroid elevation is the mechanism, meaningful in people with pre-existing hormone-sensitive conditions

Long-term safety data is limited. Caution is warranted in anyone with hormone-sensitive pathology (certain cancers, endometriosis, etc.).

Stacking Considerations

Kisspeptin + PT-141: Different mechanisms for sexual function, kisspeptin works upstream on hormones, PT-141 on central arousal pathways. Some investigators are exploring complementary effects, though no controlled trial data exists for the combination.
Kisspeptin in male hormone optimization: Discussed as an alternative or complement to hCG for preserving testicular function during TRT, but this is off-label and not clinically validated.

Clinical Trial Status

Active research is ongoing, led primarily by academic groups (Imperial College London, others). Search ClinicalTrials.gov (kisspeptin) for the most current registered trials.

Commonly Studied Dosing Protocols

In published research, kisspeptin has been examined using diverse dosing regimens, primarily in academic research settings at centers such as Imperial College London. The heterogeneity of study designs and populations has resulted in considerable variation in reported dosing approaches. The following represents commonly discussed dosing ranges based on published human trials:

Intravenous Administration

Reported dosing ranges: 0.3 mcg/kg to 6.4 mcg/kg administered as intravenous infusion or bolus. Frequency: Typically single or multiple acute doses administered during a single study session or trial period. Cycle length: Most published research protocols involved acute dosing or short-duration studies (single dose or a few doses over days to weeks), rather than chronic long-term treatment. Route: Intravenous infusion or IV bolus (medical research setting required). Evidence status: Several published human studies from Imperial College London and collaborating centers have examined kisspeptin dosing in reproductive health contexts (hypogonadism, sexual dysfunction). Studies have used variable dosing based on body weight and study objectives. See: https://pubmed.ncbi.nlm.nih.gov/23629074/ (example reference on kisspeptin-10 in hypogonadal men); search ClinicalTrials.gov for ongoing research.

Subcutaneous Administration

Reported dosing ranges: 0.64 mg to 3.2 mg of kisspeptin-10 (synthetic; IV or SubQ), though SubQ administration is less frequently reported in published literature. Frequency: Protocols vary; some research involves acute single doses while ongoing clinical trials may explore repeated dosing. Cycle length: Limited published data on long-term SubQ kisspeptin regimens. Route: Subcutaneous injection. Evidence status: Most rigorous human research involves IV administration. SubQ kisspeptin remains less thoroughly characterized in published trials, and optimal dosing for SubQ administration has not been established through formal dose-response studies.

Intramuscular Administration

Reported dosing: Limited published data. Evidence status: IM administration has been discussed in research contexts but is less common than IV in published trials. Bioavailability and pharmacokinetics of IM kisspeptin are not well characterized in the literature.

Evidence Gaps and Study Heterogeneity

Published kisspeptin studies vary substantially in dosing, study population, duration, outcome measures, and methods of administration. Most trials have been relatively small and conducted in academic research centers. No large, multisite dose-optimization trials have been published. The field remains in early-stage clinical research with no standardized dosing protocols.

Evidence Status: Published human studies of kisspeptin dosing are limited in number and geographically concentrated in academic research centers. While several well-designed trials have been published (primarily from Imperial College London), they represent diverse patient populations and research objectives, making it difficult to extract unified dosing guidelines. Optimal dosing for clinical indications (hypogonadism, sexual dysfunction) remains to be determined through future research.

Frequently Asked Questions

Is kisspeptin the same as PT-141?

No. They both affect sexual function but through completely different mechanisms. Kisspeptin works on the reproductive hormone axis (driving LH/FSH and sex steroid production). PT-141 works centrally on melanocortin receptors that modulate arousal directly. Kisspeptin is systemic and endocrine; PT-141 is acute and central.

Kisspeptin-10 vs. Kisspeptin-54, what's the difference?

Both activate the same receptor. KP-54 is the full-length endogenous peptide and has a longer half-life; KP-10 is the shortest biologically active fragment and has a shorter duration but is easier to synthesize. Human trials have used both.

Does kisspeptin raise testosterone?

Indirectly, by increasing LH, which signals the testes to produce testosterone. Unlike exogenous testosterone, it works through the natural axis and doesn't suppress fertility. Clinical data in men with hypogonadism shows measurable T increases in response to kisspeptin administration.

Why isn't kisspeptin approved if the research looks good?

Most published research is investigator-initiated academic work, not pharma-sponsored registration trials. Bringing a peptide through full FDA approval requires Phase 3 trials and massive investment. No company has yet committed to that path for a general-use kisspeptin product.

Can kisspeptin be used for fertility?

Clinical research has explored kisspeptin-54 as a trigger for oocyte maturation in IVF, with favorable OHSS (ovarian hyperstimulation syndrome) risk profile compared to hCG. This is still research, not standard clinical practice.

References

Comninos AN, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. PubMed
Mills EG, et al. Kisspeptin and Testosterone in Men with Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2254313. PubMed
Thurston L, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PubMed
Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. PubMed
Jayasena CN, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea. J Clin Endocrinol Metab. 2010;95(10):E228-E236. PubMed
Skorupskaite K, et al. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485-500. PubMed

Educational Disclaimer: This page is for educational and research purposes only. Kisspeptin is NOT FDA-approved for any medical indication in humans. This content is not medical advice, clinical guidance, or a recommendation to use this or any other peptide. No claims on this page should be interpreted as medical advice. If you are considering kisspeptin or any other investigational peptide, consult with a licensed healthcare provider who can evaluate your individual medical situation, potential interactions with other medications or conditions, and the known and unknown risks. The published human evidence for kisspeptin in sexual health and reproductive disorders comes from a limited number of small, academic research studies conducted primarily at centers such as Imperial College London. The vast majority of supporting research is preclinical (animal studies) and cannot be reliably extrapolated to human safety or efficacy. All information on this page is current as of April 2026 and reflects the available published literature at that time. This page is maintained by PeptideLibraryHub and is not affiliated with pharmaceutical companies, peptide manufacturers, or commercial vendors.